代谢组学在恶性血液肿瘤中的研究进展  

Research Progress of Metabolomics in Hematological Malignancies---Review

作　　者：王涵可 管俊 周林 WANG Han-Ke;GUAN Jun;ZHOU Lin(Department of Blood Transfusion,The Affiliated Hospital of Yangzhou University,Yangzhou 225009,Jiangsu Province,China;Department of Hematology,Northern Jiangsu People’s Hospital Affiliated to Yangzhou University,Yangzhou 225009,Jiangsu Province,China;Department of Laboratory Medicine,Northern Jiangsu People’s Hospital Affiliated to Yangzhou University,Yangzhou 225009,Jiangsu Province,China)

机构地区：[1]扬州大学附属医院输血科,江苏扬州225009 [2]扬州大学附属苏北人民医院血液病科,江苏扬州225009 [3]扬州大学附属苏北人民医院医学检验科,江苏扬州225009

出　　处：《中国实验血液学杂志》2025年第2期616-620,共5页Journal of Experimental Hematology

基　　金：扬州市重点研发项目(社会发展)专项(YZ2024103);江苏省苏北人民医院第二批医疗技术骨干培养对象B类。

摘　　要：近年来,代谢组学作为一门新兴的组学领域,已被证明在包括肿瘤在内的多种疾病的机制研究、新型生物标志物的筛选及治疗新策略的研发中具有重要的价值。本文通过简要概述代谢组学相关研究方法和技术,重点阐述代谢组学在以白血病、淋巴瘤、多发性骨髓瘤为代表的恶性血液肿瘤发生、发展机制研究,诊断、预后评估生物标志物筛选及治疗新策略研发3个方面的最新研究进展,并提出了代谢组学研究的局限性和未来研究策略,为恶性血液肿瘤的精准诊治和预后评估提供新的探索方向。In recent years,as a new omics field,metabolomics has been proved to be of great value in the study of the mechanism of occurrence and progression,the screening of new biomarkers and the development of novel therapeutic strategies in many diseases including tumors.In this review,we briefly summarized the research methods and techniques of metabolomics,and focused on the latest research progress of metabolomics in the pathogenesis of hematological malignancies represented by leukemia,lymphoma and multiple myeloma,screening of biomarkers for diagnosis and prognosis,and development of new therapeutic strategies.This article proposes the limitations of metabolomics and future research strategies,and provides a new exploration direction for accurate diagnosis and treatment as well as prognosis evaluation of hematological malignancies.

关 键 词：代谢组学 恶性血液肿瘤 生物标志物 治疗策略 研究进展 

分 类 号：R730[医药卫生—肿瘤]